Cyclacel Pharmaceuticals, Inc.

NasdaqCM:CYCC Voorraadrapport

Marktkapitalisatie: US$2.0m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Cyclacel Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Spiro Rombotis

Algemeen directeur

US$661.0k

Totale compensatie

Percentage CEO-salaris84.7%
Dienstverband CEO27.2yrs
Eigendom CEO1.5%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur8.1yrs

Recente managementupdates

Recent updates

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely

Aug 17
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely

Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis

Aug 07

Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?

Apr 15
Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?

Cyclacel CEO Spiro Rombotis - Addressing Cancer Resistance (Video)

Oct 04

Cyclacel issues key business objectives for 2021

Jan 11

Cyclacel Pharma inks securities purchase agreement for $7M

Dec 22

Cyclacel Pharmaceuticals EPS misses by $1.74

Nov 11

Analyse CEO-vergoeding

Hoe is Spiro Rombotis's beloning veranderd ten opzichte van Cyclacel Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$20m

Dec 31 2023US$661kUS$560k

-US$23m

Sep 30 2023n/an/a

-US$25m

Jun 30 2023n/an/a

-US$24m

Mar 31 2023n/an/a

-US$23m

Dec 31 2022US$764kUS$546k

-US$21m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$20m

Dec 31 2021US$1mUS$531k

-US$19m

Sep 30 2021n/an/a

-US$20m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$1mUS$531k

-US$12m

Sep 30 2020n/an/a

-US$8m

Jun 30 2020n/an/a

-US$8m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$1mUS$531k

-US$8m

Sep 30 2019n/an/a

-US$8m

Jun 30 2019n/an/a

-US$8m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$753kUS$531k

-US$7m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$14m

Mar 31 2018n/an/a

-US$15m

Dec 31 2017US$776kUS$531k

-US$15m

Compensatie versus markt: De totale vergoeding ($USD 661.05K ) Spiro } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Spiro is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Spiro Rombotis (65 yo)

27.2yrs

Tenure

US$661,049

Compensatie

Mr. Spiro George Rombotis has been President of Cyclacel Pharmaceuticals Inc. (formerly, Cyclacel Pharmaceuticals, Inc. (formerly known as Cyclacel Group plc)) since August 1997 and has been its Founding C...

Bestuursleden

NaamPositieTenureCompensatieEigendom
Spiro Rombotis
President18.6yrsUS$661.05k1.52%
$ 29.7k
Paul McBarron
Executive VP of Finance18.6yrsUS$352.62k0.82%
$ 16.1k
Brian Schwartz
Chief Medical Officer & Director3.8yrsUS$84.49k0.85%
$ 16.5k
Samuel Barker
Independent Chair of the Board10.1yrsUS$97.99k0.21%
$ 4.1k
Christopher Henney
Independent Director18.6yrsUS$136.99k0.21%
$ 4.0k
Karin Walker
Independent Director3.9yrsUS$95.49k0.21%
$ 4.2k
Edward Sikora
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Michel Marty
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Kenneth Harrap
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Stanley Kaye
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Robert Jay Spiegel
Independent Vice Chairman6.1yrsUS$115.99k0.21%
$ 4.0k
Kenneth Ferguson
Independent Director2.3yrsUS$85.49k0.20%
$ 3.8k

8.1yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CYCC wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.1 jaar).